RESIST: Understanding the Role of Depression in Heart Disease
Overview
This study will investigate the biological pathways involved in anti-depressant resistance that increase risk of cardiovascular disease in people with depression.
Full Title of Study: “Resist: What Are the Mechanisms Involved in Depression and Antidepressant Resistance That Increase Cardiovascular Risk?”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Cross-Sectional
- Study Primary Completion Date: December 2017
Detailed Description
Rationale: Depression is known to be associated with the development of cardiovascular disease and poorer prognosis after cardiac events, however the mechanisms that mediate these links are poorly understood. Inflammatory and neuroendocrine processes are thought to play an important role in this relationship. In addition, antidepressants have been shown to improve cardiac outcomes and have anti-inflammatory effects, whilst inflammation has been shown to be elevated in patients who do not respond to treatment. Several possible biomarkers for antidepressant resistance have also been demonstrated to be cardiovascular risk markers. These include acute phase inflammatory markers, such as interleukin-6 (IL-6), and hypothalamic-pituitary-adrenal axis (HPA) dysregulation. Design: This will be conducted alongside a larger pharmacological trial, PANDA, where participants will be recruited from primary care and randomized to sertraline (SSRI) or placebo. The RESIST study will compare inflammatory cardiovascular risk factors between depressed patients taking sertraline, depressed patients taking placebo and healthy controls. This will be achieved by investigating the pharmacological effect of antidepressants on gene expression, glucocorticoid and mineralocorticoid receptor function and regulatory T cell (Treg) profiles.
Arms, Groups and Cohorts
- Depressed patients taking sertraline
- Patients with depression who have been randomised to the sertraline arm in the PANDA trial
- Depressed patients taking placebo
- Patients with depression who have been randomised to the placebo arm in the PANDA trial
- Healthy controls
- Healthy participants with no history of depression
Clinical Trial Outcome Measures
Primary Measures
- Candidate gene expression
- Time Frame: 6 weeks
- Levels of RNA expression for genes associated with cardiovascular risk
- Glucocorticoid and mineralocorticoid receptor function
- Time Frame: 6 weeks
- Glucocorticoid and mineralocorticoid inhibition of lipopolysaccharide (LPS)-stimulated IL-6 levels.
- Regulatory T-cell profiles
- Time Frame: 6 weeks
- Measurement of percentages of leukocyte subsets
Participating in This Clinical Trial
Inclusion Criteria
- Depressed patients: – Meet ICD10 criteria from the Clinical Interview Schedule-Revised (CIS-R) Exclusion Criteria:
- Depressed patients: – Are taking any anti-inflammatory drugs or drugs which interfere with HPA-axis function, endothelial function, circadian rhythm or any other pathways under investigation – Unable to read, understand and/or complete questionnaires – Other psychiatric disorders: psychosis, schizophrenia, bipolar disorder, mania, hypomania, dementia, and eating disorder – Vulnerable adults – Healthy controls: – Have a history of depression – Are taking any anti-inflammatory drugs or drugs which interfere with HPA-axis function, endothelial function or circadian rhythm or any other pathways under investigation – Unable to read, understand and/or complete questionnaires – Other psychiatric disorders: psychosis, schizophrenia, bipolar disorder, mania, hypomania, dementia, and eating disorder – Vulnerable adults
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 74 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- University College, London
- Collaborator
- British Heart Foundation
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Glyn Lewis, Principal Investigator, UCL
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.